In January, 2015, the CheckMate 017 trial of the immune checkpoint inhibitor Opdivo (nivolumab) versus the standard chemo agent Taxotere (docetaxel) as second line therapy for patients with advanced squamous NSCLC was reported in a press release to be positive for a significant improvement in overall survival.

Immunotherapy Forum Video #26: Drs. Jared Weiss and Matthew Hellmann answer questions from the audience following their presentations on immunotherapy for lung cancer. Moderated by Dr. Jack West.

[powerpress]

Thoracic oncologist Dr. Ben Levy highlights what he believes was the biggest news for lung cancer patients in 2014 as well as his take on exciting clinical trials taking place in lung cancer in 2015.

Download a transcript of the video

[powerpress]

Immunotherapy Forum Video #25: In Part 2 of 2 videos, Dr.

Immunotherapy Forum Video #24: In Part 1 of 2 videos, Dr.

Immunotherapy Forum Video #23: Dr. Jared Weiss highlights what doctors know about immunotherapy treatments for lung cancer.

It was a big day for the lung cancer world. After seeing the tantalizing promise of immunotherapy for lung cancer over the past 3 years, but outside of the range of routine clinical practice, the anti-PD1 antibody,  immune checkpoint inhibitor Opdivo (nivolumab) was approved by the FDA today for previously treated patients with advanced squamous NSCLC. This was just days after it was formally available for consideration and was based on the clear benefit demonstrated in the pivotal CHECKMATE 017 trial.

In Part 2 of 2 videos about squamous lung cancer, Dr.

Dr. Thomas John of the Olivia Newton-John Cancer Center in Melbourne, Australia presents his favorite breakthroughs in lung cancer from 2014.

For those who wish to access the PDF, it's here: Thomas John, MD Top Four Lung Cancer Highlights 2014

Agree? Disagree? What are you looking forward to in 2015?

Acquired Resistance Forum Video #6: Dr. Nate Pennell of the Cleveland Clinic discussed the other options available to patients with ALK, ROS1 and EGFR lung cancer, such as chemotherapy, Avastin, and immunotherapy.

[powerpress]